Using 5-deoxy-5-[18F]fluororibose to Glycosylate Peptides for Positron Emission Tomography

Overview

Journal Nat Protoc

Specialties Biology
Pathology
Science

Date 2013 Dec 21

PMID 24356772

Citations 9

Authors

Xiang-Guo Li

Kerttuli Helariutta

Anne Roivainen

Sirpa Jalkanen

Juhani Knuuti

Anu J Airaksinen

Affiliations

Soon will be listed here.

Abstract

So far seven peptide-based (18)F-radiopharmaceuticals for diagnostic applications with positron emission tomography (PET) have entered into clinical trials. Three candidates out of these seven are glycosylated peptides, which may be explained by the beneficial influence of glycosylation on in vivo pharmacokinetics of peptide tracers. This protocol describes the method for labeling peptides with 5-deoxy-5-[(18)F]fluororibose ([(18)F]FDR) as a prosthetic group. The synthesis of [(18)F]FDR is effected by a nucleophilic fluorination step by using dried Kryptofix 2.2.2-K2CO3-K(18)F complex and a subsequent HCl-catalyzed hydrolysis. The conjugation of [(18)F]FDR to the N-terminus aminooxy (-ONH2)-functionalized peptides is carried out in anilinium buffer at pH 4.6 and at room temperature (RT, 21-23 °C), with the concentration of peptide precursors being 0.3 mM. The procedure takes about 120 min and includes two cartridge isolation steps and two reversed-phase (RP) HPLC purification steps. The quaternary methyl amine (QMA) anion exchange cartridge and the hydrophilic-lipophilic balanced (HLB) cartridge are used for the isolation of (18)F-fluoride and [(18)F]FDR-conjugated peptides, respectively. The first HPLC purification provides the (18)F-fluorinated precursor of [(18)F]FDR and the second HPLC purification is to separate labeled peptides from their unlabeled precursors. The final product is formulated in PBS ready for injection, with a radiochemical purity of >98% and a radiochemical yield (RCY) of 27-37% starting from the end of bombardment (EOB). The carbohydrate nature of [(18)F]FDR and the operational convenience of this protocol should facilitate its general use.

Citing Articles

Adventures in radiosynthesis of clinical grade [Ga]Ga-DOTA-Siglec-9.

Kakela M, Luoto P, Viljanen T, Virtanen H, Liljenback H, Jalkanen S RSC Adv. 2022; 8(15):8051-8056.

PMID: 35542034 PMC: 9078465. DOI: 10.1039/c7ra12423f.

Lipase A-Based Enantiorecognition of a Highly Strained 4-Dibenzocyclooctynol (DIBO) Used for PET Imaging.

Siren S, Dahlstrom K, Puttreddy R, Rissanen K, Salminen T, Scheinin M Molecules. 2020; 25(4).

PMID: 32079253 PMC: 7070869. DOI: 10.3390/molecules25040879.

Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats.

Elo P, Li X, Liljenback H, Helin S, Teuho J, Koskensalo K J Neuroinflammation. 2019; 16(1):252.

PMID: 31796042 PMC: 6892159. DOI: 10.1186/s12974-019-1612-3.

Convenient Preparation of F-Labeled Peptide Probes for Potential Claudin-4 PET Imaging.

Feni L, Omrane M, Fischer M, Zlatopolskiy B, Neumaier B, Neundorf I Pharmaceuticals (Basel). 2017; 10(4).

PMID: 29258264 PMC: 5748654. DOI: 10.3390/ph10040099.

Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation.

Salmi M, Jalkanen S Antioxid Redox Signal. 2017; 30(3):314-332.

PMID: 29065711 PMC: 6306676. DOI: 10.1089/ars.2017.7418.

References

Hohne A, Mu L, Honer M, Schubiger P, Ametamey S, Graham K . Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem. 2008; 19(9):1871-9. DOI: 10.1021/bc800157h. View

Beer A, Grosu A, Carlsen J, Kolk A, Sarbia M, Stangier I . [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13(22 Pt 1):6610-6. DOI: 10.1158/1078-0432.CCR-07-0528. View

Klepper F, Jahn E, Hickmann V, Carell T . Synthesis of the transfer-RNA nucleoside queuosine by using a chiral allyl azide intermediate. Angew Chem Int Ed Engl. 2007; 46(13):2325-7. DOI: 10.1002/anie.200604579. View

Ametamey S, Honer M, Schubiger P . Molecular imaging with PET. Chem Rev. 2008; 108(5):1501-16. DOI: 10.1021/cr0782426. View

McParland B, Miller M, Spinks T, Kenny L, Osman S, Khela M . The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med. 2008; 49(10):1664-7. DOI: 10.2967/jnumed.108.052126. View

Kohler J . Aniline: a catalyst for sialic acid detection. Chembiochem. 2009; 10(13):2147-50. DOI: 10.1002/cbic.200900401. View

Maschauer S, Einsiedel J, Haubner R, Hocke C, Ocker M, Hubner H . Labeling and glycosylation of peptides using click chemistry: a general approach to (18)F-glycopeptides as effective imaging probes for positron emission tomography. Angew Chem Int Ed Engl. 2009; 49(5):976-9. DOI: 10.1002/anie.200904137. View

Hausner S, Carpenter R, Bauer N, Sutcliffe J . Evaluation of an integrin αvβ6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry. Nucl Med Biol. 2012; 40(2):233-9. DOI: 10.1016/j.nucmedbio.2012.10.007. View

Holland J, Cumming P, Vasdev N . PET of signal transduction pathways in cancer. J Nucl Med. 2012; 53(9):1333-6. DOI: 10.2967/jnumed.112.105387. View

10.

Li X, DallAngelo S, Schweiger L, Zanda M, OHagan D . [18F]-5-Fluoro-5-deoxyribose, an efficient peptide bioconjugation ligand for positron emission tomography (PET) imaging. Chem Commun (Camb). 2012; 48(43):5247-9. DOI: 10.1039/c2cc31262j. View

11.

Schottelius M, Poethko T, Herz M, Reubi J, Kessler H, Schwaiger M . First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004; 10(11):3593-606. DOI: 10.1158/1078-0432.CCR-03-0359. View

12.

Beer A, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P . Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008; 49(2):255-9. DOI: 10.2967/jnumed.107.045526. View

13.

Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M . Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med. 2006; 47(4):566-73. View

14.

Gaertner F, Kessler H, Wester H, Schwaiger M, Beer A . Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1:S126-38. DOI: 10.1007/s00259-011-2028-1. View

15.

Roivainen A, Jalkanen S, Nanni C . Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1:S68-77. DOI: 10.1007/s00259-011-1987-6. View

16.

Koopmans K, Glaudemans A . Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1:S4-10. DOI: 10.1007/s00259-011-2038-z. View

17.

Miller P, Long N, Vilar R, Gee A . Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008; 47(47):8998-9033. DOI: 10.1002/anie.200800222. View

18.

Namavari M, Cheng Z, Zhang R, De A, Levi J, Hoerner J . A novel method for direct site-specific radiolabeling of peptides using [18F]FDG. Bioconjug Chem. 2009; 20(3):432-6. PMC: 2765576. DOI: 10.1021/bc800422b. View

19.

Li Y, Liu Z, Harwig C, Pourghiasian M, Lau J, Lin K . (18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor. Am J Nucl Med Mol Imaging. 2013; 3(1):57-70. PMC: 3545365. View

20.

Tolmachev V, Orlova A . Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem. 2010; 17(24):2636-55. DOI: 10.2174/092986710791859397. View